Biperiden
| Biperiden | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 311.50 g/mol [1] |
| Appearance | Crystals [1] |
| Melting point | 114 °C [1] |
| Solubility | 25.1 mg/L [1] |
| Predicted LogP | 4.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C21H29NO |
| IUPAC name | 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol |
| SMILES | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O |
| InChI | InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2 |
| InChIKey | YSXKPIUOCJLQIE-UHFFFAOYSA-N |
| CAS number | 514-65-8 |
| UNII | 0FRP6G56LD |
| PubChem CID | 2381 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 18–24 hours |
| Metabolism | Liver hydroxylation |
| Excretion | Kidney |
| Routes of administration | By mouth, intramuscular, intravenous |
| Toxicity [] | |
|---|---|
| LD50 | Dog: - oral: 340 mg/kg /Biperiden - iv: 222 mg/kg /Biperiden Rat: - ip: 270 mg/kg /Biperiden - oral: 750 mg/kg [1] |
Biperiden (also known as Biperidene, Biperidine, Biperideno, Biperidenum, Kl 373, Akineton-, α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol, 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-1-piperidinepropanol or 1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol) is a anticholinergic substance of the phenylpropylamine class.
Chemistry
Stereochemistry []
Biperiden is a racemic mixture.
Druglikeness
Lipinski's rule of five
Biperiden matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anti-parkinson drugs (N04)
- anticholinergic agents (N04A)
- tertiary amines (N04AA)
- (N04AA02)
- biperiden (N04AA02)
MeSH Classification
Mechanism of action []
Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. [1]
Interactions []
Experience reports
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 2381, Biperiden. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/2381
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Biperiden. UNII: 0FRP6G56LD. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/0FRP6G56LD
Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025. Therapeutic Goods Administration (TGA). May 2025. https://www.legislation.gov.au/F2025L00599/asmade/2025-05-28/text/original/pdf
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 07:07:00 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 07:06:56 |
| erowid | ok | 2026-11-20 07:06:57 |
| gsrs | ok | 2026-11-20 07:06:56 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014948) | 2026-11-20 07:06:56 |
| kegg | ok | 2026-11-20 07:06:57 |
| pubchem | ok | 2026-11-20 07:06:55 |
| ok | 2026-11-20 07:06:56 | |
| sider | missing (not in SIDER) | 2026-11-20 07:06:56 |
| structure | ok | 2026-11-20 07:06:56 |
| wikipedia | ok | 2026-11-20 07:06:56 |